ClinicalTrials.gg
RecruitingNCT06720727CHARMUpdated Jan 20, 2025

Craniospinal Irradiation in Histone AlteRed Midline Glioma

An interventional study of craniospinal irradiation in Glioma, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-01-20.

Sponsored by Tata Memorial Centre · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Glioma with a site in India — 8 open to participants now, 8 under way, none of them phase 3. Glioma · India.

Started
2025
with 2 others
No phase
4 of 19
3 open now
Registered
11th of 19
by date
Lead sponsor
7 of 19
Tata Memorial Centre

Among the 19 studies in Glioma with a site in India, this one is one of 3 that started in 2025, is one of 4 with no phase, and was the 11th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

8 of the 19 studies in Glioma with a site in India are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Glioma with a site in India, or all of them as a file.
02

Study summary

Paediatric H3K27/H3G34 mutant diffuse midline gliomas are high grade gliomas that arise in midline structures/cerebral hemispheres and are known to have dismal outcomes. Standard treatment includes definitive radiation therapy to primary site along with concurrent temozolomide chemotherapy following histological confirmation with a biopsy. Studies have shown poorer outcomes in the paediatric age group compared to that of adults and an increased risk to fail/recur in the leptomeninges(covering of brain and spinal cord). The following study is planned in order to assess the benefit of craniospinal irradiation(delivering radiotherapy to brain, spinal cord and its covering membrane in this high risk population. Thereby the investigator aim to improve survival in newly diagnosed histone mutant pediatric midline gliomas in the upfront setting. Patterns of disease failure, treatment related toxicities and quality of life will also be assessed as a part of this study. If proven beneficial, this study will influence how patients with this diagnosis will be treated in the future.

Read the detailed description

Introduction: Paediatric H3K27/H3G34 mutant diffuse midline gliomas (DMGs) are aggressive high-grade gliomas predominantly affecting midline structures and cerebral hemispheres. Despite aggressive therapy including radiation and chemotherapy, these tumors carry a poor prognosis, particularly in children, with frequent recurrence and high risk of leptomeningeal spread. Current standard treatment involves definitive radiation therapy to the primary site and concurrent temozolomide chemotherapy following histological confirmation via biopsy. However, outcomes remain suboptimal, prompting exploration of more intensive therapeutic strategies.

Primary objective:

To study if the addition of craniospinal irradiation to standard practice improves outcomes in pediatric diffuse midline glioma.

Secondary objectives:

  • Estimate median time to leptomeningeal dissemination and compare with historical control
  • Study patterns of failure
  • Early and late toxicities
  • Study quality of life indices
  • To estimate QTWiST (Quality of life without symptoms or toxicity)

Primary endpoint: Overall survival at 12 months

Secondary endpoints:

  • Time to leptomeningeal dissemination in months
  • Incidence of different failure patterns from clinico-radiological assessment
  • Toxicity assessment with the NCI Common Terminology Criteria for Adverse Events version 5 (CTCAE v5) during CSI(weekly), at conclusion of radiotherapy , post completion of 6 cycles adjuvant temozolomide, and in subsequent follow-ups at 3, 6, 9 and 12 months.
  • Quality of life indices using the EORTC QLQC- 30 and its BN -20 module at baseline, after completion of radiotherapy, post completion of 6 cycles adjuvant temozolomide and in subsequent follow-up visits at 3, 6, 9 and 12 months.
  • Quality of life without symptoms or toxicity in three health states TOX (toxicity), TWIST (time without symptoms) and REL (relapse) at baseline, after completion of radiotherapy, post completion of 6 cycles adjuvant temozolomide and in subsequent follow-up visits at 3, 6, 9 and 12 months.

Study setting: The study will be conducted in the department of Radiation Oncology, Neuro Oncology Disease management group

03

Conditions studied

  • Glioma

Browse trials for

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed proven histone altered diffuse midline glioma
  2. Age- ≥3 to \<18 years at time of diagnosis
  3. /Lansky Performance Score more than or equal to 70
  4. Has provided written / assent form
  5. No prior therapy except debulking surgery or biopsy

Exclusion criteria

Exclusion Criteria:

  1. Recurrent or progressive disease
  2. Clinical features or family history suggestive of Inherited Cancer Predisposition such as Constitutional Mismatch Repair Deficiency (CMMRD)
  3. Previous history of
  4. Not willing /unlikely to comply with proposed therapy and follow up
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Single arm

    Craniospinal irradiation involves delivery of radiation therapy to the whole brain, spinal cord, nerve roots, the covering meninges(leptomeninges) and subarachnoid space and provides a viable means of mitigating leptomeningeal spread and possibly improving survival.

    Radiation: craniospinal irradiation

Interventions

  • Radiationcraniospinal irradiation

    Delivering radiotherapy to brain, spinal cord and its covering membrane.

06

What researchers measure

Primary outcomes

  1. Survival Outcomes

    Overall survival- time in months between the date of diagnosis to date of death due to any cause

    Time frame: at 12 months

Secondary outcomes

  1. Leptomeningeal Dissemination

    Time to leptomeningeal dissemination (will be defined as time in months between completion of planned therapy to the date of confirmation of leptomeningeal metastasis)

    Time frame: at 12 months

  2. Patterns of failure

    Incidence of different patterns of failure from diagnosis ( the time point of measurement of the primary outcome - overall survival

    Time frame: at 12 months

  3. Any treatment emergent acute toxicity recording

    All treatment emergent acute toxicity- expected (nausea, vomiting, hematological, dermatitis and mucositis) and unexpected, will be recorded. Grading will be done for all using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5

    Time frame: Baseline , week 1 , week 2 , week 3 , week 4 , week 5 ,week 6 , conclusion of RT

  4. Quality of life indices

    Objective scoring with European Organisation For Research And Treatment Of Cancer(EORTC) Quality of Life Questionnaire(QLQC-30), brain specific module (BN 20)

    Time frame: will be done at 3 months

  5. QTWiST (Quality of life Without Symptoms or Toxicity) calculation

    Objective score calculation using mean duration in each health state weighed by a utility coefficient; from QLQC 30- BN 20 scores and the time spent in serious toxicity and without relapse.

    Time frame: will be done at 3 months

  6. Any treatment emergent late toxicity recording

    All treatment emergent late toxicity- expected and unexpected, will be recorded after completion of chemotherapy. Grading will be done for all using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.

    Time frame: After completion of 6 cycles of adjuvant chemotherapy, at 3months, 6months, 9months and 12months follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Nov 2028, 46 months after the start.

Of 131 non-industry interventional studies with no phase under Glioma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 114. This study's planned 46 months is below that.

Counting every sponsor, half of 142 studies reached it within 58 months; a quarter within 34 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Dec 6, 2024
StartActual
Jan 3, 2025
Primary completionEst.
Nov 8, 2028
CompletionEst.
Nov 8, 2028
Last update
Jan 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06720727
Lead sponsor
Tata Memorial Centre
Responsible party
Sponsor
First posted
Dec 6, 2024
Start date
Jan 3, 2025
Primary completion
Nov 8, 2028 (estimated)
Completion
Nov 8, 2028 (estimated)
Last update
Jan 20, 2025

Study contacts

Abhishek Chatterjee, MD
Contact
chatterji08@gmail.com
2224177000 ext. 6015
Abhishek Chatterjee, MD
principal investigator · Tata Memorial Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion